Mass eradication of helicobacter pylori to prevent gastric cancer: Theoretical and practical considerations

Gut and Liver

Volumn 10, Issue 1, 2016, Pages 12-26

  Lee, Yi Chia ^a,b   Chiang, Tsung Hsien ^a,c   Liou, Jyh Ming ^a,b   Chen, Hsiu Hsi ^b   Wu, Ming Shiang ^a   Graham, David Y ^d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Eradication; Helicobacter pylori; Population screening; Stomach neoplasms

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; ASTHMA; ATOPY; CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HEALTH CARE POLICY; HEALTH PROGRAM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFLAMMATORY BOWEL DISEASE; LATENT TUBERCULOSIS; MASS SCREENING; OBESITY; REVIEW; STOMACH CANCER; COMPLICATION; HEALTH CARE PLANNING; HELICOBACTER INFECTIONS; MICROBIOLOGY; STOMACH NEOPLASMS;

HEALTH PRIORITIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MASS SCREENING; STOMACH NEOPLASMS;

EID: 84957309775     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl15091     Document Type: Review

References (88)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
3. Herrero R, Parsonnet J, Greenberg ER. Prevention of gastric cancer. JAMA 2014;312:1197-1198.
4. Park JY, von Karsa L, Herrero R. Prevention strategies for gastric cancer: a global perspective. Clin Endosc 2014;47:478-489.
5. Nobelprize.org. All nobel prizes in physiology or medicine [Internet]. Stockholm: Nobel Media AB; c2015 [cited 2015 Jan 26]. Available from: http://www.nobelprize.org/nobel-prizes/medicine/laureates/.
6. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007;117:60-69.
7. IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer (IARC Working Group Reports, No. 8) [Internet]. Lyon: International Agency for Research on Cancer; 2014 [cited 2015 Nov 9]. Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
8. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-1367.
9. Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut 2005;54:735-738.
10. Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013;62:676-682.
11. Lee YC, Chiu HM, Chiang TH, et al. Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions. BMJ Open 2013;3:e003989.
12. Wilson JM, Jungner G. Principles and practice of screening for disease. WHO Chron 1968;22:473.
13. Taiwan Cancer Registry. Cancer statistics [Internet]. Taipei: Taiwan Cancer Registry; c2008 [cited 2015 Jan 5]. Available from: http://crs.cph.ntu.edu.tw/main.php.
14. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-1145.
15. Wu GH, Auvinen A, Määttänen L, et al. Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. Int J Cancer 2012;131:1367-1375.
16. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467:1114-1117.
17. Patz EF Jr, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014;174:269-274.
18. Sanduleanu S, Le Clercq CM, Dekker E, et al. Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature. Gut 2015;64:1257-1267.
19. Chiang TH, Chuang SL, Chen SL, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology 2014;147:1317-1326.
20. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943.
21. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-1859.
22. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-615.
23. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194.
24. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-1888.
25. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536-1540.
26. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of pre-cancerous gastric lesions. J Natl Cancer Inst 2006;98:974-983.
27. Li WQ, Ma JL, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst 2014;106. pii: dju116.
28. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-1249.
29. Zhou L. Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. Gastroenterology 2008;134(4 Suppl 1):A233.
30. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Heli-cobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-397.
31. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g3174.
32. Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. Effect of Helico-bacter pylori eradication on metachronous gastric cancer after en-doscopic resection of gastric tumors: a meta-analysis. Helicobacter 2014;19:243-248.
33. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664.
34. Granstrom M, Lehours P, Bengtsson C, Mégraud F. Diagnosis of Helicobacter pylori. Helicobacter 2008;13 Suppl 1:7-12.
35. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006;101: 1921-1930.
36. Lee YC, Tseng PH, Liou JM, et al. Performance of a one-step fecal sample-based test for diagnosis of Helicobacter pylori infection in primary care and mass screening settings. J Formos Med Assoc 2014;113:899-907.
37. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial sero-logical kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996;91:1138-1144.
38. Benson VS, Atkin WS, Green J, et al. Toward standardizing and reporting colorectal cancer screening indicators on an international level: the International Colorectal Cancer Screening Network. Int J Cancer 2012;130:2961-2973.
39. Porras C, Nodora J, Sexton R, et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control 2013;24:209-215.
40. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Heli-cobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-514.
41. Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci 2014;59:1698-1709.
42. Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and retreat initial treatment failures. Helicobacter 2006;11:418-424.
43. Graham DY, Dore MP. Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis. In: Hunt RH, Tyt-gat GN, eds. Helicobacter pylori: basic mechanisms to clinical cure 1998. Dordrecht: Springer, 1998:426-440.
44. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013;381:205-213.
45. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-186.e3.
46. Lee SY. Current progress toward eradicating Helicobacter pylori in East Asian countries: differences in the 2013 revised guidelines between China, Japan, and South Korea. World J Gastroenterol 2014;20:1493-1502.
47. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helico-bacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-726.
48. Romano M, Marmo R, Cuomo A, et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helico-bacter pylori. Clin Gastroenterol Hepatol 2003;1:273-278.
49. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-563.
50. Demir M, Gokturk HS, Ozturk NA, Arslan H, Serin E, Yilmaz U. Clarithromycin resistance and efficacy of clarithromycin-contain-ing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South Med J 2009;102:1116-1120.
51. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010;59:1465-1470.
52. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010;8:36-41.e1.
53. Sirimontaporn N, Thong-Ngam D, Tumwasorn S, Mahachai V. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol 2010;105:1071-1075.
54. Yakoob J, Abid S, Abbas Z, Jafri SN. Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area. Br J Biomed Sci 2010;67:197-201.
55. Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter 2011;16:146-152.
56. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-913.
57. Mahachai V, Sirimontaporn N, Tumwasorn S, Thong-Ngam D, Vilaichone RK. Sequential therapy in clarithromycin-sensitive and-resistant Helicobacter pylori based on polymerase chain reaction molecular test. J Gastroenterol Hepatol 2011;26:825-828.
58. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013;145:121-128.e1.
59. World Health Organization (WHO). What is an "organized" screening programme [Internet]. Geneva: WHO; 2015 [cited 2015 Dec 8]. Available from: http://cancer-code-europe.iarc.fr/index.php/en/ecac-12-ways/screening-recommandation/key-points-about-can-cer-screening/213-what-is-an-organized-screening-programme.
60. Liou JM, Chen CC, Chang CY, et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013;68:450-456.
61. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-1153.
62. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290-308.
63. Lee YC, Lin JT, Wu HM, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 2007;16:875-885.
64. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150-154.
65. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999;159:142-148.
66. Harris RA, Owens DK, Witherell H, Parsonnet J. Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori? Helicobacter 1999;4:69-76.
67. Mason J, Axon AT, Forman D, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 2002;16:559-568.
68. Roderick P, Davies R, Raftery J, et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 2003;10:148-156.
69. Wang Q, Jin PH, Lin GW, Xu SR, Chen J. Cost-effectiveness of He-licobacter pylori screening to prevent gastric cancer: Markov decision analysis. Zhonghua Liu Xing Bing Xue Za Zhi 2003;24:135-139.
70. Xie F, Luo N, Lee HP. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helico-bacter pylori to prevent gastric cancer: a markov model. World J Gastroenterol 2008;14:3021-3027.
71. Xie F, O'Reilly D, Ferrusi IL, et al. Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J Am Coll Radiol 2009;6:317-323.
72. Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 2009;124:157-166.
73. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology 2005;129:1910-1917.
74. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esopha-geal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588-590.
75. Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis 2008;198:553-560.
76. Wu MS, Lee WJ, Wang HH, Huang SP, Lin JT. A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med 2005;165:1552-1555.
77. Papamichael K, Konstantopoulos P, Mantzaris GJ. Helicobacter pylori infection and inflammatory bowel disease: is there a link? World J Gastroenterol 2014;20:6374-6385.
78. Perry S, de Jong BC, Solnick JV, et al. Infection with Helicobacter pylori is associated with protection against tuberculosis. PLoS ONE 2010;5:e8804.
79. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719-731.e3.
80. Lee YC, Yen AM, Tai JJ, et al. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut 2009;58:174-181.
81. Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication? A meta-analysis. Am J Gastroenterol 2010;105:1007-1013.
82. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999;319:1562-1565.
83. Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006;4:709-716.
84. Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol 2013;23(6 Pt B):492-501.
85. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008;40:650-658.
86. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. rating the quality of evidence: study limitations (risk of bias). J Clin Epidemiol 2011;64:407-415.
87. Choi HS, Lee SY, Kim JH, et al. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm. J Dig Dis 2014;15:293-298.
88. Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroen-terol Hepatol 2013;10:495-500.